Bedel Financial Consulting, Inc. Denali Therapeutics Inc. Transaction History
Bedel Financial Consulting, Inc.
- $691 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
214Shares Held
121MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$348 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$333 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$286 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$248 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$180 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.39B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...